Across 5 research centers, investigators evaluated the impact of eculizumab on thymoma-associated myasthenia gravis, a severe ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25Deepening responses observed over time in ...

Cartesian Therapeutics (RNAC) highlighted its recent progress and outlined its 2025 strategic priorities across its pipeline of mRNA cell ...

About 100 days into the CEO role at Kyverna Therapeutics, Warner Biddle has determined the strategic priorities for the ...

The FDA has granted priority review to a Biologics License Application for nipocalimab to treat individuals with generalized ...

Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, ...

Brodie Studio and Gallery, 219 E. Henry St., showcases multi-media works of Gena Brodie, who faces forward despite illness.

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.

Johnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for ...

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed.

The prevalence and incidence rates of myasthenia gravis in the elderly US population have increased from 2006 to 2019.